Novo Nordisk stock fell pre-market after missing Q2 earnings expectations, with revenue at $11.95B vs. $11.97B expected. Sales increased by 16%, driven by diabetes drug Ozempic and weight loss drug Wegovy. The company faces competition challenges, including lawsuits against copycat drugs impacting growth.

Outgoing CEO Lars Jørgensen blames compounded weight loss drugs for reducing sales growth to 8%-14%. Novo Nordisk filed 14 new lawsuits to combat copycat drugs. Jørgensen claims over one million patients use unauthorized versions of their drug, impacting the company’s market position and growth potential.

Eli Lilly’s new prescriptions are 60% higher than Novo Nordisk’s, despite Novo’s exclusive deal with CVS for weight loss drugs. Novo faces price negotiations for Medicare next year. President Trump demanded Novo provide its lowest price to Medicaid population, adding pressure on the company’s pricing strategies.

Jørgensen stated Medicaid enrollees already receive low prices. Novo did not address the demand for lower cash pricing to all patients, but highlighted NovoCare’s 10% market penetration. Novo Nordisk faces challenges in maintaining market share and pricing strategies amid increasing competition and regulatory pressures.

Read more at Yahoo Finance: Novo Nordisk reports second quarter earnings missing Wall Street estimates on slower GLP-1 sales